Randomized, placebo-controlled study on long-term efficacy of sorbinil, published in the Sept. 1 New England Journal of Medicine. Study concludes that the aldose reductase inhibitor, "as a metabolic intervention targeted against a specific biochemical consequence of hyperglycemia, can improve the neuropathologic lesions of diabetic neuropathy." The study is part of the Pfizer/National Eye Institute's large, multicenter investigation of sorbinil. It found that the 10 sorbinil-treated patients had a 42% decrease in nerve sorbitol content and a 3.8 fold increase in the percentage of regenerating myelinated nerve fibers after one-year of treatment. Pfizer said it expects analysis of all sorbinal trial data to be completed later this year. The company has begun considering related compounds.
You may also be interested in...
Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics.
The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.
Limiting interactions to two-dimensional settings will hinder collaboration, innovation and the mentoring of younger employees, Merck & Co. CEO Kenneth Frazier says. Frazier, who will retire in June, is looking forward to returning to public service but says "politics with a capital P is not my thing."